Next-gen obesity drug helps patients lose 28% of body weight

NEW YORK >> Eli Lilly said today its experimental obesity drug helped patients lose more than 28% of their weight over a year and a half in a key trial that allows the company to seek regulatory approval and potentially launch the next-generation drug next year.

See the original article at: Honolulu Star-Advertiser